Pfizer Inc. (NYSE:PFE) Shares Sold by MCF Advisors LLC

MCF Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 24.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,044 shares of the biopharmaceutical company’s stock after selling 5,257 shares during the period. MCF Advisors LLC’s holdings in Pfizer were worth $449,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. boosted its position in shares of Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 945 shares during the period. Los Angeles Capital Management LLC boosted its holdings in shares of Pfizer by 3.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 29,864 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 899 shares during the period. Gryphon Financial Partners LLC increased its position in shares of Pfizer by 43.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 8,194 shares in the last quarter. E Fund Management Co. Ltd. raised its holdings in shares of Pfizer by 22.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 13,922 shares of the biopharmaceutical company’s stock valued at $401,000 after acquiring an additional 2,514 shares during the period. Finally, Principal Securities Inc. purchased a new stake in shares of Pfizer in the 4th quarter valued at approximately $2,393,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on PFE shares. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays lifted their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

NYSE PFE opened at $28.51 on Friday. The firm has a market cap of $161.55 billion, a P/E ratio of -475.09, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The stock’s 50-day moving average is $29.05 and its two-hundred day moving average is $28.04. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $35.28. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the business earned $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were paid a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.89%. Pfizer’s payout ratio is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.